Physician profile
Patrick D Williams
NPI 1154306777
$16,688.88
in general payments reported to CMS, 2019-2025
19 companies · $60.35 in 2025
The $60.35 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,048 · 2020: $5,304 · 2021: $2,801 · 2022: $169 · 2023: $1,824 · 2024: $3,482 · 2025: $60.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,533 · Food and Beverage: $816 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,533.00 |
| Food and Beverage | $816.49 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $13,298.82 | 2019-2024 | Eylea Hd, Eylea |
| Carl Zeiss Meditec, INC. | $1,459.07 | 2020 | |
| Novartis Pharmaceuticals Corporation | $655.78 | 2019-2021 | |
| Genentech USA, INC. | $314.66 | 2019-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $207.20 | 2023-2024 | Syfovre |
| Coherus Oncology, INC. | $153.53 | 2022-2023 | |
| Ocular Therapeutix, INC. | $149.84 | 2024-2025 | Dextenza |
| Neotract INC. | $138.26 | 2019 | |
| Astellas Pharma US INC | $116.25 | 2023-2024 | Izervay |
| Alimera Sciences, INC. | $69.24 | 2019-2024 | Yutiq, Iluvien |
| Abbvie INC. | $28.50 | 2024 | |
| Sandoz INC. | $27.93 | 2024 | Cimerli |
| Genentech, INC. | $24.03 | 2019 | |
| Bausch & Lomb Americas INC. | $23.88 | 2022 | |
| Allergan, INC. | $21.89 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.